Clinical Trials
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Latest Clinical Trial Results
Innovative Anti-hypoxia Drug to Improve Treatment of Refractory Tumors
Newton, MA – September 8, 2008 – Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutic compounds...
The results indicate that IN-105 is safe and well tolerated by Type 2 diabetic patients and is able to significantly drop 2-hour post prandial glucose in a dose-related manner.
Bangalore, India September 8, 2008- Biocon Limited, India's premier...
Tekmira Also Presents at Charles River Biotech Symposium
VANCOUVER, BRITISH COLUMBIA--(Marketwire) - Sept. 8, 2008 - Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that one of its collaborators, the National Cancer...
LONDON, Sept. 8, 2008--A neglected member of an important family of proteins could boost the effectiveness of an exciting new group of cancer drugs – reveals a study in Cancer Cell* today (Monday).
HSP90 inhibitors are a new group of...
LONDON, Sept. 8, 2008--Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrate that saxagliptin produced reductions across all key measures of glucose control studied...
- Clinical study of over 500 patient samples well on track for completion in Q4 2008
- Interim analysis representing approximately half of the cases demonstrates statistical significance for primary endpoint of prostate...
SEATTLE--(BUSINESS WIRE)--Sep 5, 2008 - Cutting-edge discoveries in ovarian cancer research including developments on improving therapeutics for patients diagnosed with ovarian cancer and early detection of the disease were revealed as the 7th...
N. BILLERICA, Mass.--(BUSINESS WIRE)--Sep 5, 2008 - Lantheus Medical Imaging, a worldwide leader in diagnostic imaging, announced today that the company's leading imaging agent, Cardiolite(R) (Kit for the Preparation of Technetium Tc99m Sestamibi...
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Sept. 8, 2008 - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) announced today positive results of clinical work on its Pill-Plus(TM) "triple hormone" therapy oral contraceptive. The Pill-Plus adds a third hormone,...
DANBURY, Conn.--(BUSINESS WIRE)--Sept. 8, 2008 - At the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Rome, Biodel Inc. (Nasdaq: BIOD) today reported results from its two pivotal Phase III clinical trials...
Results Demonstrate Safety and Efficacy of First-in-Class Neurally Acting Anti-Migraine Agent (NAAMA) for the Treatment of Acute Migraine
LONDON, September 6, 2008 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company...
Data Presented At European Diabetes Conference Demonstrate Biological Activity, Positive Safety Profile and Potential Dosing of Once Per Month or Longer
ROME, Sept. 8, 2008 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA)...
LIVINGSTON, N.J.--(BUSINESS WIRE)--Sep 8, 2008 - Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that its third party data management consultants have confirmed that the results from the Company's recently completed Phase II clinical...
ROCHESTER, N.Y.--(BUSINESS WIRE)--Sep 8, 2008 - iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarkers, today announced the successful completion of the industry's largest validation study for an automated ECG analysis...
ROME--(BUSINESS WIRE)--Sep 8, 2008 - Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA(TM) (saxagliptin), an investigational selective inhibitor...
- 90% of genotype 2 or 3 patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) -
PRINCETON, N.J., September 08, 2008 /PRNewswire-FirstCall/ -- Pharmasset, Inc. announces the...
ROME, September 08, 2008 /PRNewswire-FirstCall/ -- Novo Nordisk , a global healthcare company, presented data from a phase 3 clinical study (LEAD(TM) 4) today at the 44th annual meeting of the European Association for the Study of Diabetes that...
M. D. Anderson-led team develops first-ever for African-Americans, expands previous model
HOUSTON, Sept. 5, 2008 – Lung cancer risk prediction models are enhanced by taking into account risk factors by race and by measuring DNA repair...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sep 5, 2008 - Sarah Cannon Research Institute (SCRI) investigators have found that "smart bomb" therapies are effective in treating breast cancer patients while minimizing side effects.
Howard A. Burris III, M.D.,...
The study will be presented today in advance of the American Society for Clinical Oncology Breast Cancer Symposium.
Approximately 30 percent of breast cancer cells have an excess amount of the HER2 protein on their surface, which makes the...
More...
